The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation ofliverlipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium/glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.本發明提供一種醫藥組成物，有用於作為因肝臟脂肪異常堆積引起之疾病之發展抑制劑。本發明之醫藥組成物之特徵為含有鈉/葡萄糖共輸送體2型抑制劑作為有效成分，由於具有抑制肝臟異常堆積脂肪之作用，故作為一般性脂肪肝，甚至非酒精性脂肪肝(NAFL)、非酒精性脂肪肝炎(NASH)、過營養性脂肪肝、糖尿病性脂肪肝、酒精性脂肪肝或中毒性脂肪肝等之發展抑制劑極為適合。
